Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mannheim – page 17

357 clinical trials in Mannheim, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mannheim at a glance
357
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

357 trials in Mannheim

Open in trial search

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Alcohol use disorder

Not recruiting

A Study of Brenipatide Compared to Placebo in Adults with Moderate-to-Severe Alcohol Use Disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zelenectide pevedotin
  • Sponsor:Bicycletx Limited

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Activated PI3 kinase delta syndrome

Not recruiting

Study on the Effects of Leniolisib in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Leniolisib Phosphate
  • Sponsor:Pharming Technologies B.V.

Meningitis meningococcal

Not recruiting

Study on the Safety and Immune Response of MenABCWY Vaccine in Healthy Adolescents Aged 11-14 with Meningococcal Meningitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mannheim

What the registry says about research in the country

01 Neurodegenerative Disorders

Clinical investigations focusing on Alzheimer's Disease and ALS, including trials of new therapeutic compounds for early-stage dementia and innovative treatments for motor neuron disease.

  • Early-stage Alzheimer's diagnostic tools
  • Novel drug therapies for neurodegenerative conditions
  • Disease progression monitoring

Research aims to improve brain amyloid clearance and evaluate new treatment approaches for neurological disorders.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for gastric cancer, melanoma, and breast cancer, with a focus on targeted therapies and immunological approaches.

  • HER2-expressing cancers
  • Metastatic melanoma treatments
  • Lymphoma therapies

Advanced treatments combining immunotherapy with established protocols to improve patient outcomes.

03 Inflammatory Conditions

Studies addressing inflammatory disorders, particularly focusing on Crohn's Disease, ulcerative colitis, and uveitis, testing novel therapeutic combinations.

  • Gastrointestinal disorders
  • Autoimmune conditions
  • Combination therapy approaches

Innovative treatment strategies aimed at improving disease management and patient quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.